Table 3 Results of multivariate analysis showing the significant prognostic factors for different survival outcomes in nasopharyngeal carcinoma patients
Factor | Hazard ratio | 95% CI | P |
|---|---|---|---|
Overall survival | |||
Chemotherapy (IMRT vs. IMRT/CT) | 1.152 | 0.346–3.834 | 0.818 |
Age (≤45 years vs. > 45 years) | 1.307 | 0.347–4.930 | 0.692 |
Sex (male vs. female) | 0.909 | 0.239–3.465 | 0.889 |
TNM stage (II vs. III [T3N0M0]) | 5.797 | 1.768–19.007 | 0.004 |
Disease-free survival | |||
Chemotherapy (IMRT vs. IMRT/CT) | 0.840 | 0.303–2.328 | 0.738 |
Age (≤45 years vs. > 45 years) | 1.049 | 0.351–3.135 | 0.932 |
Sex (male vs. female) | 0.590 | 0.166–2.092 | 0.414 |
TNM stage (II vs. III [T3N0M0]) | 4.990 | 1.772–14.047 | 0.002 |
Locoregional relapse-free survival | |||
Chemotherapy (IMRT vs. IMRT/CT) | 1.476 | 0.242–9.011 | 0.673 |
Age (≤45 years vs. > 45 years) | 0.832 | 0.136–5.080 | 0.842 |
Sex (male vs. female) | 1.015 | 0.212–3.457 | 0.973 |
TNM stage (II vs. III [T3N0M0]) | 1.575 | 0.176–14.099 | 0.685 |
Distant metastasis-free survival | |||
Chemotherapy (IMRT vs. IMRT/CT) | 0.905 | 0.259–3.155 | 0.875 |
Age (≤45 years vs. > 45 years) | 1.075 | 0.270–4.271 | 0.919 |
Sex (male vs. female) | 0.950 | 0.241–3.736 | 0.941 |
TNM stage (II vs. III [T3N0M0]) | 4.705 | 1.322–16.751 | 0.017 |